Información del artículo
El Texto completo está disponible en PDF
Bibliogrífia
[1.]
J.A. Sacristán, L. Prieto, T. Huete, A. Artigas, X. Badía, C. Chinn, et al.
Coste-efectividad de drotrecogina alfa (activada) en el tratamiento de la sepsis grave en España.
Gac Sanit, 18 (2004), pp. 50-57
[2.]
G.R. Bernard, J.L. Vincent, P.F. Laterre, S.P. LaRosa, J.F. Dhainaut, A. López-Rodríguez, et al.
Efficacy and safety of recombinant human activated protein C for severe sepsis.
N Engl J Med, 344 (2001), pp. 699-709
[3.]
J.P. Siegel.
Assessing the use of activated protein C in the treatment of severe sepsis.
N Engl J Med, 347 (2002), pp. 1030-1034
[4.]
Food and Drug Administration. Product approval information. Disponible en: www.fda.gov/cder/biologics/products/droteli112101.htm..
[5.]
Xigris. European Public Assessment Report (EPAR) Sicentific Discussion. Disponible en: www.emea.eu.int/humandocs/Humans/EPAR/xigris/xigris.htm.
[6.]
NICE Final Appraisal Determination-Dotrecogin alfa (activated) for severe sepsis [consultado 4/6/2004]. Disponible en: www.nice.org.uk/pdf/FAD_Sepsis_Drotrecogin.pdf.
[7.]
NHS Scottland. Update of Glasgow Formulary 2002 (updated and sent to all prescribers). Disponible en: http://www.show.scot.nhs.uk/gghb/adtc/Latest%20news/Update%20to%20Formulary%20valid%20until%20August%2003.pdf.
[8.]
Patented medicine prices review board reports on new patented drugs for human use. Disponible en: http://www.pmprbcepmb.gc.ca/CMFiles/pm04-Xigris-e22JHA-2182004-8142.pdf.
[9.]
Positive Recommendations made by the PBAC (Pharmaceutical Benefits Advisory Committee). Disponible en: http://www.health.gov.au/pbs/pharm/listing/pbacrec/pbacrecjun.htm.
[10.]
Comisión de la Transparence Agence française de sécurité sanitaire des produits de santé. Disponible en: http://agmed.sante.gouv.fr/htm/5/avisct/data/ct031334.pdf.
[11.]
D.C. Angus, W.T. Linde-Zwirble, G. Clermont, D.E. Ball, B.R. Basson, E.W. Ely, et al.
for the PROWESS Investigators. Cost effectiveness of drotrecogin alfa (activated) (Xigris?) in severe sepsis.
Crit Care Med, 31 (2003), pp. 1-11
Copyright © 2004. Sociedad Española de Salud Pública y Administración Sanitaria
